Results 141 to 150 of about 948,070 (312)
Saúde e inovação: uma abordagem sistêmica das indústrias da saúde
Partindo do reconhecimento da importância da geração e da difusão de inovações para o desenvolvimento sócio-econômico nos países capitalistas e do caráter sistêmico, institucional e histórico desse processo, o trabalho procura evidenciar a necessidade de
Carlos Augusto Grabois Gadelha +2 more
doaj
Regulatory policy and the location of bio-pharmaceutical FDI in Europe [PDF]
This paper examines the relationship bewteen cross-country differences in drug price regulation and the location of biopharmaceutical Foreign Direct Investment (FDI) in Europe.
Megan Macgarvie, Pamina Koenig
core
Development of human monoclonal antibodies against TARM1 by yeast display
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe +5 more
wiley +1 more source
This study investigated a novel WST‐8‐based assay for evaluating d‐Amino acid oxidase (DAO) inhibitors. We confirmed its effectiveness using known inhibitors and found that uremic toxins possess relatively weak inhibitory activity compared to existing drugs.
Kahoko Miyake +4 more
wiley +1 more source
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel +8 more
wiley +1 more source
Premium policy? Getting better value from the PBS [PDF]
Overview: Poor implementation of a policy to get better value for PBS spending is costing government $320 million a year and raising questions about pharmaceutical industry involvement in drug pricing. The therapeutic group premium policy, introduced in
Peter Breadon, Stephen Duckett
core
Bisphenol A (BPA), a common chemical in plastics, exerts dual effects on bladder cancer cells: low doses promote growth and migration, while high doses suppress growth and migration. Multi‐omics and bioinformatics reveal BPA acts via MAPK and inflammatory pathways.
Shaomin Niu +10 more
wiley +1 more source
Digital twins to accelerate target identification and drug development for immune‐mediated disorders
Digital twins integrate patient‐derived molecular and clinical data into personalised computational models that simulate disease mechanisms. They enable rapid identification and validation of therapeutic targets, prediction of drug responses, and prioritisation of candidate interventions.
Anna Niarakis, Philippe Moingeon
wiley +1 more source
5‐Aminolevulinic acid combined with ferric ammonium citrate (5‐ALA/FAC) stimulates dermal papilla cell activity and promotes hair follicle growth. The treatment enhances ERK and AKT signaling, increases hair‐inductive gene expression, and restores dermal papilla function suppressed by dihydrotestosterone and oxidative stress, resulting in enhanced hair
Han‐Wook Ryu, Eok‐Soo Oh, Sewoon Kim
wiley +1 more source
R&D Portfolios and Pharmaceutical Licensing [PDF]
We examine how R&D portfolios of drug pipelines affect pharmaceutical licensing, controlling firm size, diversity, and competitors in R&D and product markets.
Junichi Nishimura, Yosuke Okada
core

